• Explore /
  • Poster
  • / Randomized, double-blind, placebo-controlled, phase II trial of first-line platinum/docetaxel with or without erlotinib (E) in patients (pts) with recurrent and/or metastatic (R/M) head and neck squamous cell carcinomas (HNSCCs).

Randomized, double-blind, placebo-controlled, phase II trial of first-line platinum/docetaxel with or without erlotinib (E) in patients (pts) with recurrent and/or metastatic (R/M) head and neck squamous cell carcinomas (HNSCCs).

Abstract Poster

Authors

William Nassib William

William Nassib William Jr.

The University of Texas MD Anderson Cancer Center, Houston, TX

William Nassib William Jr., Lei Feng , Merrill S. Kies , Salmaan Ahmed , George R. Blumenschein Jr., Bonnie S. Glisson , Erminia Massarelli , Faye M. Johnson , Charles Lu , Vassiliki Papadimitrakopoulou , Kathryn A. Gold , Rachel Leigh Theriault , John Heymach , Edward S. Kim

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Head and Neck Cancer

Track

Head and Neck Cancer

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT01064479

Citation

J Clin Oncol 35, 2017 (suppl; abstr 6017)

DOI

10.1200/JCO.2017.35.15_suppl.6017

Abstract #

6017

Poster Bd #

5

Abstract Disclosures

Similar Posters

First Author: A. Dimitrios Dimitrios Colevas

First Author: Aarti K. Bhatia

First Author: Makoto Tahara

First Author: Lori J. Wirth